A Phase I, Single Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability and Pharmacokinetics of Extended Release Tablets of AZD3241 After Administration of Multiple Ascending Doses in Healthy Male and Female Volunteers Including Food Effect.
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2018
At a glance
- Drugs AZD 3241 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- 06 Jun 2018 Population pharmacokinetic model for AZD3241 was developed using data from one phase 1 MAD study in healthy subjects (study 02, D0490C00002, NCT00914303), and one phase 2 safety and tolerability study (study 23,D0490C00023, NCT02388295), results published in the Journal of Clinical Pharmacology
- 24 Mar 2018 Data from one phase I study (NCT00914303) and one phase II study in Multiple System Atrophy (NCT02388295) trial was used to develop PopPK model, results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 01 Apr 2010 Actual patient number (77) added as reported by ClinicalTrials.gov.